#VisualAbstract: Adjuvant nivolumab may be promising for treatment of completely resected Merkel cell carcinoma
1. Disease-free survival at 24 months was 84% in the nivolumab group compared to 73% in the observation group. 2. ...
Tag: immunotherapy
Adjuvant nivolumab may be promising for treatment of completely resected Merkel cell carcinoma
1. Disease-free survival at 24 months was 84% in the nivolumab group compared to 73% in the observation group. 2. ...
Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE)
1. This phase 2, single-arm, multicenter trial found that in HER2-positive breast cancer patients demonstrating resistance to trastuzumab, the combination ...
![Macitentan better than placebo for preventing progression of pulmonary arterial hypertension [SERAPHIN Trial]](https://www.2minutemedicine.com/wp-content/uploads/2013/08/ca68dc0329bef0b42ccae7b6656a0f_gallery-350x250.jpg)
Sotorasib superior to docetaxel for treatment of KRASG12C-positive non-small-cell lung cancer
1. Patients allocated to the sotorasib group reported increased progression-free survival compared to the docetaxel group. 2. Sotorasib was generally ...
#VisualAbstract: Adjuvant pembrolizumab improves distant metastasis-free survival in stage IIB-C melanoma
Click to read this study in The Lancet Oncology.
Nivolumab plus ipilimumab improves recurrence-free survival in patients with resected advanced melanoma
1. 4-year recurrence-free survival was significantly higher with nivolumab plus ipilimumab compared to placebo. 2. Overall survival was significantly higher ...
Atezolizumab does not reduce post-resection recurrence in patients with renal cell carcinoma
1. Atezolizumab was associated with non-significantly increased disease-free survival compared to placebo (57.2 months vs. 49.5 months). 2. Serious adverse ...
Stereotactic body radiation does not improve outcomes in patients with advanced Merkel cell carcinoma receiving nivolumab and ipilimumab
1. Objective response rate was not significantly different in patients treated with stereotactic body radiotherapy compared to those without. 2. ...
#VisualAbstract: Pembrolizumab-based therapy is more effective with increasing PD-L1 expression in head and neck squamous cell carcinomas
Click to read this study in the Journal of Clinical Oncology.
#VisualAbstract: FOLFOX in combination with nivolumab and trastuzumab improves survival in metastatic ERBB2⁺ esophagogastric adenocarcinoma
Click to read this study in JAMA Oncology.